The Joint Meeting of the IBDW and MBDSC is an ACCME accredited activity and will enrich the attendees with a concentrated, focused menu of current information across the spectrum of metabolic bone diseases that will serve science and patient care alike.

Who Should Attend?

Those professionals who work in the following areas: Primary Care, Endocrinology, Nephrology, Rheumatology, Endocrinology, Gynecology, Orthopedics and skeletal Radiologists.

The International Bone Densitometry Workshop (IBDW) educational mission is to update the metabolic bone field in the cutting-edge advances in the radiological assessments of skeletal micro architecture and bone quality. The topics of discussion and presentation by true experts in this field include, for example, presenting the advancements in micro-MRI, high resolution central and peripheral QcT, finite element analysis, measurements of cortical porosity, and other newer imaging modalities in bone.

The program of the IBDW is tailored to be both scientific as well as clinical with ample time provided for open discussion between all faculty and attendees; and, presentations of original research by young investigators.

The IBDW enhances the education of both basic scientists as well as clinicians interested in understanding the forthcoming tools that will soon be available in clinical medicine to measure bone quality and provide a means to facilitate dual energy x-ray absorptiometries (DXA) fracture risk assessment capacity.

The Metabolic Bone Disease Society of Colorado (MBDSC) mission is to broaden the practical knowledge of clinical metabolic bone disease; and provide attendees with updated clinical data on a wide variety of real-world clinical challenges in bone. For the 2012 (26^th annual meeting) the topics to be covered include current challenges in bisphosphonate use (such as "drug-holidays" and "atypical femur fractures); application of biochemical markers of bone turnover in the management of post-menopausal osteoporosis; recent advances in the application of FRAX for risk assessment; and emerging newer therapies coming soon for the treatment of osteoporosis.

In addition, this year's meeting will also include presentations by the world's 2 top experts in parathyroid hormone biology on the challenges of management of patients across the spectrum of hyperparathyroidism and uses of current and emerging PTH molecules in the treatment of osteoporosis.